Skip to NavigationSkip to content

AstraZeneca buys rights to Orexo respiratory programme

Published on 21/03/16 at 12:38pm

AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million.

The deal centres on the rights to Orexo’s candidate OX-CLI, which treats conditions like asthma and COPD.

With the acquisition, AstraZeneca takes up an option established in 2013, when the companies signed a deal allowing AstraZeneca to conduct research and evaluation of compounds in the OX-CLI programme, and giving it the option of a full asset transfer.  

Nikolaj Sørensen, chief executive of Orexo, says: “I am pleased that AstraZeneca has decided to exercise the company’s option to acquire this novel and innovative program. It is an important sign of confidence in OX-CLI, from one of the leading companies within respiratory diseases. We look forward to follow the continued product development of OX-CLI, which we believe has the potential to become an important new medication in the treatment of respiratory diseases.

“Pushing the boundaries of science to transform disease management and improve asthma patient outcomes is central to our respiratory strategy, and the OX-CLI compounds could enable us to offer a completely new personalised treatment for patients whose condition is caused by the dysregulation of leukotrienes. I am particularly pleased to see this new collaboration come to fruition as it could help to further strengthen the Nordic Life Science eco-system,” adds Maarten Kraan, vice president, RIA Innovative Medicines unit, AstraZeneca.

Joel Levy

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches